Adults age ≥18 with IDH2-mutated MDS, CMML and AML in remission (CR) after allo-HSCT with hematologic recovery post-alloHSCT. No active, steroid-refractory GVHD. This evidence concerns the gene IDH2 and chronic myelomonocytic leukemia.